- Home
- GHRS vs DGICA Comparison
GHRS vs DGICA Comparison
Compare GHRS & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- DGICA
- Stock Information
- Founded
- GHRS 2018
- DGICA 1986
- Country
- GHRS Ireland
- DGICA United States
- Employees
- GHRS N/A
- DGICA 851
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- DGICA Property-Casualty Insurers
- Sector
- GHRS Health Care
- DGICA Finance
- Exchange
- GHRS Nasdaq
- DGICA Nasdaq
- Market Cap
- GHRS 849.8M
- DGICA 680.2M
- IPO Year
- GHRS 2021
- DGICA N/A
- Fundamental
- Price
- GHRS $12.31
- DGICA $19.07
- Analyst Decision
- GHRS Strong Buy
- DGICA Hold
- Analyst Count
- GHRS 8
- DGICA 1
- Target Price
- GHRS $30.63
- DGICA $18.00
- AVG Volume (30 Days)
- GHRS 187.6K
- DGICA 123.6K
- Earning Date
- GHRS 05-08-2025
- DGICA 07-24-2025
- Dividend Yield
- GHRS N/A
- DGICA 3.85%
- EPS Growth
- GHRS N/A
- DGICA 1206.68
- EPS
- GHRS N/A
- DGICA 2.03
- Revenue
- GHRS N/A
- DGICA $993,637,805.00
- Revenue This Year
- GHRS N/A
- DGICA $3.27
- Revenue Next Year
- GHRS N/A
- DGICA $4.01
- P/E Ratio
- GHRS N/A
- DGICA $9.32
- Revenue Growth
- GHRS N/A
- DGICA 5.29
- 52 Week Low
- GHRS $6.00
- DGICA $12.26
- 52 Week High
- GHRS $20.50
- DGICA $21.12
- Technical
- Relative Strength Index (RSI)
- GHRS 52.37
- DGICA 43.74
- Support Level
- GHRS $12.43
- DGICA $18.96
- Resistance Level
- GHRS $13.15
- DGICA $19.74
- Average True Range (ATR)
- GHRS 0.99
- DGICA 0.56
- MACD
- GHRS -0.14
- DGICA -0.09
- Stochastic Oscillator
- GHRS 41.03
- DGICA 15.19
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.